HRP20190059T1 - Pripravci za liječenje boli i/ili upale - Google Patents

Pripravci za liječenje boli i/ili upale

Info

Publication number
HRP20190059T1
HRP20190059T1 HRP20190059TT HRP20190059T HRP20190059T1 HR P20190059 T1 HRP20190059 T1 HR P20190059T1 HR P20190059T T HRP20190059T T HR P20190059TT HR P20190059 T HRP20190059 T HR P20190059T HR P20190059 T1 HRP20190059 T1 HR P20190059T1
Authority
HR
Croatia
Prior art keywords
inflammation
pain
preparations
treatment
Prior art date
Application number
HRP20190059TT
Other languages
English (en)
Croatian (hr)
Inventor
Cristina CARRENO SERRAÏMA
Wim Van Den Nest
Antonio Ferrer Montiel
Maria CAMPRUBÍ ROBLES
Jimena FERNÁNDEZ CARNEADO
Berta Ponsati Obiols
Original Assignee
Bcn Peptides, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bcn Peptides, S.A. filed Critical Bcn Peptides, S.A.
Publication of HRP20190059T1 publication Critical patent/HRP20190059T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Cell Biology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
HRP20190059TT 2008-07-24 2009-07-24 Pripravci za liječenje boli i/ili upale HRP20190059T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200802210A ES2356883B1 (es) 2008-07-24 2008-07-24 Composición para el tratamiento del dolor y/o la inflamación.
PCT/EP2009/005381 WO2010009892A2 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation
EP09777419.4A EP2318033B8 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation

Publications (1)

Publication Number Publication Date
HRP20190059T1 true HRP20190059T1 (hr) 2019-03-08

Family

ID=41462205

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190059TT HRP20190059T1 (hr) 2008-07-24 2009-07-24 Pripravci za liječenje boli i/ili upale

Country Status (24)

Country Link
US (2) US20110206752A1 (enExample)
EP (1) EP2318033B8 (enExample)
JP (1) JP5920916B2 (enExample)
KR (1) KR20110056491A (enExample)
CN (1) CN102164610B (enExample)
AR (1) AR072610A1 (enExample)
AU (1) AU2009273471C1 (enExample)
BR (1) BRPI0911743B1 (enExample)
CA (1) CA2731880C (enExample)
CY (1) CY1121125T1 (enExample)
DK (1) DK2318033T3 (enExample)
ES (2) ES2356883B1 (enExample)
HR (1) HRP20190059T1 (enExample)
HU (1) HUE042083T2 (enExample)
IL (1) IL210810B (enExample)
LT (1) LT2318033T (enExample)
MX (1) MX2011000868A (enExample)
PL (1) PL2318033T3 (enExample)
PT (1) PT2318033T (enExample)
RU (1) RU2515054C2 (enExample)
SG (1) SG192548A1 (enExample)
SI (1) SI2318033T1 (enExample)
TR (1) TR201900542T4 (enExample)
WO (1) WO2010009892A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961510A1 (fr) * 2010-06-17 2011-12-23 Oreal Utilisation comme agent de traitement de la transpiration humaine ; nouveaux derives d'acide amine ; compositions les contenant
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
DK3415157T3 (da) 2011-10-28 2020-10-19 Neostrata Company Inc N-acyldipeptidderivater og anvendelser deraf
WO2013070808A1 (en) 2011-11-07 2013-05-16 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
US9687669B2 (en) 2011-11-09 2017-06-27 John Stephan Wearable light therapy apparatus
CA2859915A1 (en) * 2012-01-03 2013-07-11 Ruey J. Yu N-acylpeptide derivatives and their uses
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
DE102014007423A1 (de) * 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
RU2580280C2 (ru) * 2014-07-08 2016-04-10 Общество с ограниченной ответственностью "НИТРОЗДРАВ" Композиция для местного применения для снижения или снятия болевого синдрома
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20190083809A1 (en) 2016-07-27 2019-03-21 Z2020, Llc Componentry and devices for light therapy delivery and methods related thereto
JP7227903B2 (ja) * 2016-11-30 2023-02-22 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド 皮膚、毛髪、爪および／もしくは粘膜の処置ならびに／またはケアに有用な化合物
KR102293250B1 (ko) * 2017-09-18 2021-08-26 애니젠 주식회사 활성물질-헥사펩타이드 복합체 및 이를 포함하는 화장료 조성물
EP3691618A1 (en) 2017-10-06 2020-08-12 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
ES3060502T3 (en) 2018-06-13 2026-03-26 Acraf Peptides having inhibitory activity on neuronal exocytosis
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
WO2020182970A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Process for making stable bacterial extracts and their use as pharmaceuticals
WO2020259447A1 (zh) 2019-06-24 2020-12-30 湖南方升泰医药科技有限公司 金属络合物的新应用
CN116731111A (zh) * 2022-10-14 2023-09-12 深圳市维琪科技股份有限公司 合成肽及其组合物和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
ATE215832T1 (de) * 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) * 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
ES2362301T3 (es) * 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
CN102408470A (zh) * 2005-12-23 2012-04-11 洛桑大学 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
KR20090041066A (ko) * 2007-10-23 2009-04-28 성균관대학교산학협력단 신경전달물질 배출을 조절하는 합성 펩타이드

Also Published As

Publication number Publication date
AU2009273471B2 (en) 2014-04-17
EP2318033A2 (en) 2011-05-11
LT2318033T (lt) 2019-02-11
CN102164610A (zh) 2011-08-24
EP2318033B8 (en) 2019-02-27
CY1121125T1 (el) 2019-12-11
AU2009273471C1 (en) 2014-08-21
WO2010009892A2 (en) 2010-01-28
CA2731880A1 (en) 2010-01-28
MX2011000868A (es) 2011-06-09
DK2318033T3 (en) 2019-02-04
SG192548A1 (en) 2013-08-30
BRPI0911743B1 (pt) 2021-11-16
ES2714357T3 (es) 2019-05-28
RU2011105280A (ru) 2012-08-27
KR20110056491A (ko) 2011-05-30
PT2318033T (pt) 2019-01-24
US20190184054A1 (en) 2019-06-20
AR072610A1 (es) 2010-09-08
TR201900542T4 (tr) 2019-02-21
BRPI0911743A2 (pt) 2015-07-07
EP2318033B1 (en) 2018-10-17
WO2010009892A8 (en) 2011-02-24
RU2515054C2 (ru) 2014-05-10
ES2356883B1 (es) 2012-02-22
JP5920916B2 (ja) 2016-05-18
AU2009273471A1 (en) 2010-01-28
US20110206752A1 (en) 2011-08-25
CA2731880C (en) 2016-12-13
ES2356883A1 (es) 2011-04-14
IL210810A0 (en) 2011-04-28
IL210810B (en) 2018-04-30
WO2010009892A3 (en) 2010-05-14
SI2318033T1 (sl) 2019-02-28
PL2318033T3 (pl) 2019-04-30
CN102164610B (zh) 2014-04-09
JP2011528678A (ja) 2011-11-24
HUE042083T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
HRP20182135T1 (hr) Pripravci za i postupci liječenja poremećaja povezanih s ige
BRPI0917378A2 (pt) tratamento da transpiracao e da hiperidrose
PL2282675T3 (pl) System do zabiegu kosmetycznego i obrazowania
DK2114419T3 (da) Natriummetaarsenit til anvendelse i behandling af smerte og inflammation
HRP20180660T1 (hr) Sustavi i postupci za liječenje tkiva prostate
IL248696B (en) Compositions comprising l-ornithine and at least one of phenylacetate and phenylbutyrate for treating inflammation
SI2894165T1 (sl) Postopki in sestavki za zdravljenje motenj povezanih s komplementom
EP2083876A4 (en) WOUND CARE AND TREATMENT METHOD
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
EP2278999C0 (en) EAR PREPARATIONS FOR THE TREATMENT OF EAR DISEASES AND CONDITIONS
LT2318033T (lt) Kompozicija, skirta skausmo ir (arba) uždegimo gydymui
EP2205196A4 (en) HAIR CARE COMPOSITIONS AND METHODS OF HAIR TREATMENT
EP2334315A4 (en) MEANS AND METHOD OF TREATMENT TREATMENT
BRPI1009847A2 (pt) conectores médicos e métodos de uso
DK2245199T3 (da) Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
SMT201600182B (it) Ligandi sigma per l'uso nella prevenzione e/o nel trattamento del dolore post-operatorio
BRPI0718129A2 (pt) Método para o tratamento de partículas pigmentares e composições farmacêuticas para o cuidado pessoal compreendendo as referidas partículas pigmentare
EP2651407A4 (en) 3-METHANSULFONYLPROPIONITRILE FOR THE TREATMENT OF INFLAMMATION AND PAIN
PL1993559T3 (pl) Leczenie niedoboru i deficytu witaminy d z zastosowaniem 25-hydroksywitaminy d2 i 25-hydroksywitaminy d3
HRP20150117T1 (xx) Pripravci kolagenaze g i kolagenaze h za lijeäśenje bolesti koje ukljuäśuju promjene kolagena
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
PL2632452T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
EP2739244A4 (en) SYSTEMS, METHODS, AND IMPLANTS FOR TREATING PROLAPS OR INCONTINENCE
DK2297106T3 (da) Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande